Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Supplemental material
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article
Advertisement

Corrigendum Free access | 10.1172/jci.insight.120932

ALX receptor ligands define a biochemical endotype for severe asthma

Isabell Ricklefs, Ioanna Barkas, Melody G. Duvall, Manuela Cernadas, Nicole L. Grossman, Elliot Israel, Eugene R. Bleecker, Mario Castro, Serpil C. Erzurum, John V. Fahy, Benjamin M. Gaston, Loren C. Denlinger, David T. Mauger, Sally E. Wenzel, Suzy A. Comhair, Andrea M. Coverstone, Merritt L. Fajt, Annette T. Hastie, Mats W. Johansson, Michael C. Peters, Brenda R. Phillips, Bruce D. Levy, and the National Heart Lung and Blood Institute’s Severe Asthma Research Program- Investigators

Find articles by Ricklefs, I. in: JCI | PubMed | Google Scholar

Find articles by Barkas, I. in: JCI | PubMed | Google Scholar

Find articles by Duvall, M. in: JCI | PubMed | Google Scholar

Find articles by Cernadas, M. in: JCI | PubMed | Google Scholar

Find articles by Grossman, N. in: JCI | PubMed | Google Scholar

Find articles by Israel, E. in: JCI | PubMed | Google Scholar

Find articles by Bleecker, E. in: JCI | PubMed | Google Scholar

Find articles by Castro, M. in: JCI | PubMed | Google Scholar

Find articles by Erzurum, S. in: JCI | PubMed | Google Scholar

Find articles by Fahy, J. in: JCI | PubMed | Google Scholar

Find articles by Gaston, B. in: JCI | PubMed | Google Scholar

Find articles by Denlinger, L. in: JCI | PubMed | Google Scholar

Find articles by Mauger, D. in: JCI | PubMed | Google Scholar

Find articles by Wenzel, S. in: JCI | PubMed | Google Scholar

Find articles by Comhair, S. in: JCI | PubMed | Google Scholar

Find articles by Coverstone, A. in: JCI | PubMed | Google Scholar

Find articles by Fajt, M. in: JCI | PubMed | Google Scholar

Find articles by Hastie, A. in: JCI | PubMed | Google Scholar

Find articles by Johansson, M. in: JCI | PubMed | Google Scholar

Find articles by Peters, M. in: JCI | PubMed | Google Scholar

Find articles by Phillips, B. in: JCI | PubMed | Google Scholar

Find articles by Levy, B. in: JCI | PubMed | Google Scholar

Published March 22, 2018 - More info

Published in Volume 3, Issue 6 on March 22, 2018
JCI Insight. 2018;3(6):e120932. https://doi.org/10.1172/jci.insight.120932.
Copyright © 2018, American Society for Clinical Investigation
Published March 22, 2018 - Version history
View PDF

Related article:

ALX receptor ligands define a biochemical endotype for severe asthma
Isabell Ricklefs, … , Bruce D. Levy, the National Heart Lung and Blood Institute’s Severe Asthma Research Program-3 Investigators
Isabell Ricklefs, … , Bruce D. Levy, the National Heart Lung and Blood Institute’s Severe Asthma Research Program-3 Investigators
Levels of the ALX receptor ligands LXA4 and SAA serve as a new asthma biochemical endotype for non-Type 2, steroid resistant inflammation in severe asthma.
Clinical Medicine Inflammation Pulmonology

ALX receptor ligands define a biochemical endotype for severe asthma

  • Text
  • PDF
Abstract

BACKGROUND. In health, inflammation resolution is an active process governed by specialized proresolving mediators and receptors. ALX/FPR2 receptors (ALX) are targeted by both proresolving and proinflammatory ligands for opposing signaling events, suggesting pivotal roles for ALX in the fate of inflammatory responses. Here, we determined if ALX expression and ligands were linked to severe asthma (SA). METHODS. ALX expression and levels of proresolving ligands (lipoxin A4 [LXA4], 15-epi-LXA4, and annexin A1 [ANXA1]), and a proinflammatory ligand (serum amyloid A [SAA]) were measured in bronchoscopy samples collected in Severe Asthma Research Program-3 (SA [n = 69], non-SA [NSA, n = 51] or healthy donors [HDs, n = 47]). RESULTS. Bronchoalveolar lavage (BAL) fluid LXA4 and 15-epi-LXA4 were decreased and SAA was increased in SA relative to NSA. BAL macrophage ALX expression was increased in SA. Subjects with LXA4loSAAhi levels had increased BAL neutrophils, more asthma symptoms, lower lung function, increased relative risk for asthma exacerbation, sinusitis, and gastroesophageal reflux disease, and were assigned more frequently to SA clinical clusters. SAA and aliquots of LXA4loSAAhi BAL fluid induced IL-8 production by lung epithelial cells expressing ALX receptors, which was inhibited by coincubation with 15-epi-LXA4. CONCLUSIONS. Together, these findings have established an association between select ALX receptor ligands and asthma severity that define a potentially new biochemical endotype for asthma and support a pivotal functional role for ALX signaling in the fate of lung inflammation. TRIAL REGISTRATION. Severe Asthma Research Program-3 (SARP-3; ClinicalTrials.gov NCT01606826) FUNDING Sources. National Heart, Lung and Blood Institute, the NIH, and the German Society of Pediatric Pneumology.

Authors

Isabell Ricklefs, Ioanna Barkas, Melody G. Duvall, Manuela Cernadas, Nicole L. Grossman, Elliot Israel, Eugene R. Bleecker, Mario Castro, Serpil C. Erzurum, John V. Fahy, Benjamin M. Gaston, Loren C. Denlinger, David T. Mauger, Sally E. Wenzel, Suzy A. Comhair, Andrea M. Coverstone, Merritt L. Fajt, Annette T. Hastie, Mats W. Johansson, Michael C. Peters, Brenda R. Phillips, Bruce D. Levy, the National Heart Lung and Blood Institute’s Severe Asthma Research Program-3 Investigators

×

Original citation: JCI Insight. 2017;2(14):1–14. https://doi.org/10.1172/jci.insight.93534

Citation for this corrigendum: JCI Insight. 2018;3(6):e120932. https://doi.org/10.1172/jci.insight.120932

Following the publication of this article, the authors became aware that there was an error in calculating the FEV1 percentage predicted, FVC percentage predicted, and FEV1/FVC percentage predicted values for subjects of mixed European descent in the SARP cohort. Correcting this error resulted in lower FEV1 and FVC percentage predicted values and slightly higher FEV1/FVC percentage predicted values — and required corrections to the spirometry data presented in Table 1, Figure 2, Figure 5F, and Supplemental Figure 2, A and B. These corrections do not change the finding that lipoxin A4 levels positively correlate with lung function in asthma and that subjects with SAAhiLXA4lo levels have lower lung function than subjects with SAAloLXA4hi levels nor do they alter the conclusions of the study.

Figure 2

Figure 5

Table 1

Clinical characteristics and bronchoalveolar lavage leukocytes for subjects undergoing bronchoscopyA

The corrected versions of Figure 2, Figure 5F, and Table 1 are below. The posted supplemental data have been updated.

The authors regret the errors.

Supplemental material

View Supplemental data

Footnotes

See the related article at ALX receptor ligands define a biochemical endotype for severe asthma.

Version history
  • Version 1 (March 22, 2018): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Supplemental material
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts